Passman Rod S
Northwestern University Feinberg School of Medicine, Chicago, IL.
J Innov Card Rhythm Manag. 2017 Jan 15;8(1):2575-2582. doi: 10.19102/icrm.2017.080104. eCollection 2017 Jan.
The management of atrial fibrillation (AF) is among the most challenging aspects of cardiology and uncertainties abound concerning stroke assessment and stroke risk reduction. Currently, AF is viewed as a dichotomous variable (fully present or absent) when it comes to stroke risk; there is no regard to the amount of AF either spontaneously or due to rhythm control strategies. For this reason, monitoring in patients with a known AF history, particularly after ablation, has focused on easily measured outcomes such as time to recurrence. However, emerging data suggest that thresholds exist between stroke risk and AF quantity as measured by either duration or burden. As a result, there is an increasing interest in long-term continuous monitoring following a rhythm control strategy to assess efficacy beyond typical symptom reduction. Insertable cardiac monitors (ICMs) with AF-sensing algorithms and remote data transmission capabilities can be used for this purpose, and wearable devices with similar functions are on the horizon. In addition to their diagnostic potential, these tools are also being used therapeutically with efforts to target anticoagulation therapy only in response to AF episodes.
心房颤动(AF)的管理是心脏病学中最具挑战性的方面之一,在中风评估和中风风险降低方面存在诸多不确定性。目前,在中风风险方面,AF被视为一个二分变量(完全存在或不存在);无论是自发的还是由于节律控制策略导致的AF量都未被考虑。因此,对有AF病史的患者进行监测,尤其是在消融术后,重点关注易于测量的结果,如复发时间。然而,新出现的数据表明,中风风险与通过持续时间或负荷测量的AF量之间存在阈值。因此,人们越来越关注节律控制策略后的长期连续监测,以评估除典型症状减轻之外的疗效。具有AF感知算法和远程数据传输功能的植入式心脏监测器(ICM)可用于此目的,具有类似功能的可穿戴设备也即将出现。除了其诊断潜力外,这些工具还被用于治疗,努力仅针对AF发作进行抗凝治疗。